The CD19 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Ca Ski human cervical carcinoma cell line. This product features targeted disruption of the CD19 gene, resulting in a mixed population of cells lacking functional CD19 protein. The polyclonal pool provides a heterogeneous knockout model for bulk population analyses, eliminating the B-lymphocyte-specific CD19 antigen and offering a clean genetic background for non-hematopoietic studies.
The parental Ca Ski cell line is an adherent epithelial cell line isolated from a cervical epidermoid carcinoma. It harbors integrated HPV-16 DNA, with viral oncoproteins E6 and E7 targeting p53 degradation and Rb inactivation, respectively, thereby maintaining the transformed state. Widely used in cancer biology, Ca Ski cells serve as a model for HPV-associated malignancies, signal transduction studies, and drug sensitivity profiling. Their epithelial lineage provides a platform for investigating non-hematopoietic aspects of gene function, including ectopic expression of lineage-restricted antigens.
CD19 is a B-lymphocyte-specific transmembrane glycoprotein that functions as a co-receptor for the B-cell receptor (BCR). Engagement of the BCR leads to phosphorylation of CD19 by Src family kinases, notably Lyn and Fyn, enabling recruitment of the p85 regulatory subunit of PI3K. This event generates PIP3, recruiting and activating AKT at the membrane, and subsequently triggers ERK, NF-??B, and PLC??2-driven calcium mobilization. CD19 cooperates with CD21, CD81, and CD225 within a co-receptor complex that synergistically enhances BCR signal transduction. Key downstream transducers include BTK, Vav, and the adaptor protein Grb2, which orchestrate B-cell developmental and proliferative responses.
In Ca Ski cells, CD19 is not natively expressed; therefore, this knockout model provides a stringent negative control by eliminating any trace expression. The polyclonal knockout population allows assessment of CD19-targeted therapies, such as CAR-T cells and bispecific antibodies, on an epithelial background lacking the antigen, facilitating off-target and cross-reactivity analyses. Because CD19’s interaction network??involving Lyn, PI3K, AKT, and NF-??B??intersects with pathways commonly altered in solid tumors, these cells enable dissection of non-canonical CD19 functions in carcinoma. The knockout guarantees that any observed molecular or pharmacological effects are CD19-dependent.
This polyclonal knockout cell product is suitable for flow cytometry validation of CD19 antibodies, Western blot confirmation of antigen depletion, and RT-qPCR transcript analysis. It serves as an essential negative target for evaluating CD19-directed immunotherapies, including CAR-T and bispecific T-cell engager platforms. Researchers may also employ these cells to explore non-canonical CD19 roles in epithelial tumor models, validate CRISPR screen hits, or conduct migration, invasion, and drug sensitivity assays with CD19-targeted agents. The polyclonal nature supports robust population-level experiments. For further inquiries, please contact Ascent Research.
